

## MANAGING PATIENTS' CARE AFTER A FRACTURE

For women with osteoporosis after menopause at high risk for fracture, starting a new treatment can raise a lot of questions. You can help them find answers and stay motivated to achieve their bone health goals by introducing them to Bone Matters™, a patient support program.

### THREE QUICK WAYS TO SIGN UP

It's easy to help your patients enroll before they leave the office.



**FAX**  
1-866-790-4994



**ONLINE**  
[evenity.com/signup](https://www.evenity.com/signup)



**TEXT**  
Text **ENROLL to 89183**

### PATIENTS RECEIVE THESE HELPFUL RESOURCES DURING TREATMENT



#### WELCOME PACKAGE

Includes lifestyle tips and bone-building facts, discusses the importance of keeping up with EVENITY™ treatments, and more.



#### COURTESY TEXT REMINDERS\*

Reminds patients to schedule their monthly dose so they can stay on track with their treatment.



#### MONTHLY e-NEWSLETTERS

Includes fracture facts and explains the importance of building bone and of a follow-up treatment.



#### LIFESTYLE TIPS

Calcium-rich recipes, exercises to help support bone strength, and more for women living with postmenopausal osteoporosis.

\*Program is intended for the limited purpose of delivering courtesy reminder notifications to remind patients to schedule their next dose of EVENITY™. However, it is up to the patient to ensure she obtains her next dose in a timely manner and in accordance with her doctor's instruction. Please go to [www.evenity.com](http://www.evenity.com) for the full Program details and information.

### Indication

EVENITY™ is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

The anabolic effect of EVENITY™ wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY™ use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive agent should be considered.

### Important Safety Information

**POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH**  
**EVENITY™ may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY™ should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY™ should be discontinued.**

Please see additional Important Safety Information on reverse side.

## Important Safety Information

### **POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH**

**EVENTITY™ may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENTITY™ should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENTITY™ should be discontinued.**

In a randomized controlled trial in postmenopausal women, there was a higher rate of major adverse cardiac events (MACE), a composite endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke, in patients treated with EVENTITY™ compared to those treated with alendronate.

**Contraindications:** EVENTITY™ is contraindicated in patients with hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating therapy with EVENTITY™. EVENTITY™ is contraindicated in patients with a history of systemic hypersensitivity to romosozumab or to any component of the product formulation. Reactions have included angioedema, erythema multiforme, and urticaria.

**Hypersensitivity:** Hypersensitivity reactions, including angioedema, erythema multiforme, dermatitis, rash, and urticaria have occurred in EVENTITY™-treated patients. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of EVENTITY™.

**Hypocalcemia:** Hypocalcemia has occurred in patients receiving EVENTITY™. Correct hypocalcemia prior to initiating EVENTITY™. Monitor patients for signs and symptoms of hypocalcemia, particularly in patients with severe renal impairment or receiving dialysis. Adequately supplement patients with calcium and vitamin D while on EVENTITY™.

**Osteonecrosis of the Jaw (ONJ):** ONJ, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients receiving EVENTITY™. A routine oral exam should be performed by the prescriber prior to initiation of EVENTITY™. Concomitant administration of drugs associated with ONJ (chemotherapy, bisphosphonates, denosumab, angiogenesis inhibitors, and corticosteroids) may increase the risk of developing ONJ. Other risk factors for ONJ include cancer, radiotherapy, poor oral hygiene, pre-existing dental disease or infection, anemia, and coagulopathy.

For patients requiring invasive dental procedures, clinical judgment should guide the management plan of each patient. Patients who are suspected of having or who develop ONJ should receive care by a dentist or an oral surgeon. In these patients, dental surgery to treat ONJ may exacerbate the condition. Discontinuation of EVENTITY™ should be considered based on benefit-risk assessment.

**Atypical Femoral Fractures:** Atypical low-energy or low trauma fractures of the femoral shaft have been reported in patients receiving EVENTITY™. Causality has not been established as these fractures also occur in osteoporotic patients who have not been treated.

During EVENTITY™ treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be evaluated to rule out an incomplete femur fracture. Interruption of EVENTITY™ therapy should be considered based on benefit-risk assessment.

**Adverse Reactions:** The most common adverse reactions ( $\geq 5\%$ ) reported with EVENTITY™ were arthralgia and headache.

EVENTITY™ is a humanized monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity.

**Please see accompanying EVENTITY™ full Prescribing Information, including Medication Guide.**

  
**EVENTITY™**  
(romosozumab-aqqg)  
injection 105 mg/1.17 mL